Search
Page 9 of 61
Selecting an LC-MS system for quantitation of pharmaceutical drug development
We understand you are busy, needing to prioritize running instruments, reporting results and managing your laboratory to meet deadlines. We created a solution guide to explain how SCIEX systems fit in the drug development pipeline to save you time evaluating options.
Tags: check, data, development, discovery, drug, Drug development, drug discovery, guide, information, knowledge, large, machine, money, Regulatory, Regulatory solutions, result, science, small, solution, study, system, technology, work
October 29, 2024
Nitrosamines: Where are we now?
Nitrosamines are a large group of N-nitroso compounds that share a common functional N-N=O group. They are produced by a chemical reaction between a nitrosating agent and a secondary or tertiary amine. Back in 2018, nitrosamines suddenly found themselves in the spotlight when they were unexpectedly detected in medications for high blood pressure. Since then, they have been found in several other prescription medications, including those for heartburn, acid reflux and diabetes, resulting in manufacturers recalling some common medications.
Tags: company, daily, data, day, dose, food, group, identification, job, knowledge, limit, machine, maximum, Nitrosamines, number, pharma impurity analyses, science, sensitive, software, technology, tertiary, work
October 10, 2024
PFAS analysis in food: a robustness study in sensitivity and stability
The combination of per- and polyfluoroalkyl substances (PFAS) testing, trace-level regulatory requirements and complex MS applications can be intimidating. In a recent webinar, now available on demand, SCIEX PFAS expert Craig Butt demonstrated how the new SCIEX 7500+ system can help make PFAS testing easier.
Tags: 7500+, cycle time, data, food, food extract, high, job, lc system, machine, matrix, model, money, number, period, PFAS, qtof system, robust, software, study, system, system sciex, testing, user, work
September 27, 2024
FDA’s final rule on LDTs: what does it mean for clinical laboratories?
On April 29, 2024, the U.S. Food and Drug Administration (FDA) announced a final rule regulating laboratory developed tests (LDTs) as in vitro diagnostic devices (IVDs) under the Federal Food, Drug and Cosmetic Act (FD&C Act). This rule amends FDA’s regulations to state that in vitro diagnostic tests “manufactured” by clinical laboratories fall within the scope of the FDA regulatory oversight and is poised to dramatically shift the way clinical diagnostic laboratories in the United States develop and offer LDTs in the future. Read this blog post for a basic overview of the scope, intent and implications of this final rule, including the regulatory requirements, exceptions and timeline for implementation.
Tags: book, care, clinical diagnostics, control, date, enforcement, file, final, information, job, laboratory, law, machine, order, policy, Regulatory, review, rule, stage, test, work
September 17, 2024
Detecting low levels of drugs and their metabolites in hair and nail samples using LC-MS/MS
You probably have heard of testing blood and urine samples for the presence of drugs and their metabolites. But do you know about the benefits of hair and nail analysis? In a recent webinar, Tina Binz, Deputy Head of the Center for Forensic Hair Analysis, University of Zurich, discussed the benefits of developing comprehensive and sensitive LC-MS/MS for the detection of low-level drugs and metabolites in keratinized matrices.
Tags: affect, analysis, blog, body hair, drug, drug analysis, drug like, Forensic toxicology, hair, Hair and nail analysis, head, human, marker, nail, old, period, research, result, sample, science, see, stress, tell, time
August 20, 2024
LC-MS system replacement: Are you ready?
Meeting deadlines in a bioanalysis laboratory can be a big challenge. Older, less sensitive and less reliable LC-MS systems make it even more difficult. Even the disruption caused by the installation and validation can be disconcerting and delay decisions. Does this sound familiar?
Tags: analysis, bioanalysis, computer, increase, information, laboratory, machine, model, money, OS software, plasma, power, problem, QTRAP 6500+, read, sample, sensitive, software, system, time, volume, work
August 16, 2024
An overview: LC-MS analysis of targeted protein degraders and their metabolites
Targeted protein degraders (TPD) are a relatively new therapeutic modality that opens the potential to target disease-causing proteins. These disease-causing proteins have been highly challenging for traditional small-molecule therapeutics to treat, making TPDs an exciting new therapeutic modality.
Tags: analysis, dissociate, drug, EAD, fragment, identification, information, item, machine, Metabolomics, MetId, object, product, professional, protein, research, science, scientist, study, target, technique, therapeutic, work
August 14, 2024
Pure and simple: Understanding LNP analytics for better mRNA-based drugs
A few years ago, it was discovered that messenger RNA (mRNA) encapsulated in lipid nanoparticles (LNPs) could result in mRNA adducts due to the breakdown products of N-oxide impurities. The ionizable lipids used in LNPs are especially susceptible to forming N-oxide impurities.
Tags: adam crowe, lipid nanoparticle, lnp, LNP analytics, mrna, mRNA-based drugs
July 3, 2024
Is the next life-changing drug waiting to be analyzed in your laboratory?
In drug discovery laboratories, there is often a need to generate trusted analytical data on hundreds of thousands of drug candidates to allow confident decisions to be made. Sample prep, instrument run time, and data processing are all challenges that must be overcome.
Tags: drug discovery, Echo® MS+ system with ZenoTOF 7600 system, HTS
June 24, 2024
Mass spec data across the cultivated meat value chain
We recently had the opportunity to chat with Alex Ward, PhD, Principal Consultant, Arta Bioanalytics to discover more about his work in developing transcriptomics and metabolomics data interpretation for the cultivated meat sector. As a specialist in multi-omics approaches, Alex is driving R&D, production and regulatory processes for the industry. Below are Alex’s responses to a few questions we asked, sharing his knowledge with the SCIEX community to drive the future of cultivated meat.
Tags: Alternative Proteins, Cultured Meats, food, Omics
June 7, 2024
Page 9 of 61